Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities

Zinger Key Points
  • Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in additional neurodegenerative diseases.
  • Passage Bio is pursuing potential partnership opportunities for pediatric lysosomal storage disease programs.
Loading...
Loading...

Passage Bio Inc PASG announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with granulin (GRN) mutations

FTD is a form of early-onset dementia (memory loss). 

  • Dose 1 of PBFT02 was generally well-tolerated in patients 2 and 3, who received an enhanced steroid regimen following protocol amendment.
  • Patient 1 received a low level of immunosuppression and experienced two SAEs that were both asymptomatic and consistent with an immune response.
  • Following patient 1, the protocol was amended to increase the steroid regimen for patients 2 and 3.
  • No evidence of dorsal root ganglion (DRG) toxicity, as measured by nerve conduction studies, and no complications related to ICM administration were observed across any of the three patients.
  • Dose 1 of PBFT02 treatment resulted in a 3.6 to 6.6-fold increase in cerebrospinal fluid (CSF) progranulin (PGRN) at day 30 (n=3) relative to baseline. 
  • CSF PGRN increased to supraphysiologic levels of 10.7 to 17.3 ng/mL at day 30, exceeding the range found in healthy adult controls of 3.3 to 8.2 ng/mL (n=61).
  • CSF PGRN remained at supraphysiologic levels at six months with a concentration of 27.3 ng/mL (n=1).
  • Plasma PGRN levels remained below levels found in healthy adult controls through the available follow-up period across all patients.

The company also shared updated strategic priorities to optimize its portfolio for treating neurodegenerative conditions further.

  • Continuing clinical development of PBFT02 to treat FTD-GRN.
  • Pursuing PBFT02 in additional adult neurodegenerative diseases, including FTD-C9orf72, ALS, and Alzheimer's disease.
  • Prioritizing Huntington's disease preclinical program through existing Penn Gene Therapy Program partnership.
  • Pursuing potential partnership opportunities for clinical-stage pediatric programs in GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy.

Price Action: PASG shares are up 7.77% at $0.82 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...